Novartis med fails in higher-dosage trial; Abbott touts Humira for RA remission;

> Novartis failed to prove that more Glivec is better: In a clinical trial, doubling doses of the cancer drug was no more effective than giving the usual dose. Report

> Abbott Laboratories said long-term data showed its drug Humira, in combination with methotrexate, led to remission of rheumatoid arthritis for up to seven years. Report

> Teva got tentative FDA approval to market its generic version of Novartis' Diovan, which is used for the treatment of hypertension. Release

> European regulators have given GlaxoSmithKline's cancer drug Tyverb--sold as Tykerb in the U.S.--conditional approval, clearing it for launch but asking for more clinical data. Report

> Generic drug maker Bentley Pharmaceuticals said its board approved the spin-off of its drug delivery business into a new company named CPEX Pharmaceuticals Inc. Report

> Genentech's Susan Desmond-Hellmann, president of product development, outlined the biotech giant's development strategy to a group at the Goldman Sachs healthcare conference. In addition to testing new uses of its cancer blockbusters, Desmond-Hellman says the company will push hard to advance new therapies in the neuroscience and infectious disease areas. Report

> Two big suppliers to the drug development business are merging. Invitrogen has agreed to acquire all of the shares of Applera's Applied Biosystems in a $6.7 billion cash and stock deal. Merger report

> The prolific Harvard/MIT scientist Robert Langer, whose ideas have spawned a string of biotech start-ups, has won the €800,000 Millennium Technology Prize. Report

> Eli Lilly is forking over a $35 million upfront payment to nail down the worldwide licensing rights to TransPharma Medical's ViaDerm-hPTH osteoporosis product and a non-exclusive license to its ViaDerm drug delivery system. Report

> Jazz Pharmaceuticals says it needs to extend the development time line for two key drug programs, a move that triggered a decision to lay off 33 workers, or eight percent of its workforce. Layoff report

And Finally... Drug companies could save millions thanks to a new technology to monitor crystals as they form, University of Leeds researchers said. Release

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.